William N Whiteley1, Douglas Thompson2, Gordon Murray2, Geoff Cohen2, Richard I Lindley2, Joanna Wardlaw2, Peter Sandercock2. 1. From the Centre for Clinical Brain Sciences (W.N.W., G.C., J.W., P.S.) and Centre for Population Health Sciences (D.T., G.M.), University of Edinburgh, United Kingdom; Neurological & Mental Health Division, George Institute for Global Health, University of Sydney, Australia (R.I.L.); and Neuroimaging Sciences, Edinburgh, United Kingdom (J.W.). william.whiteley@ed.ac.uk. 2. From the Centre for Clinical Brain Sciences (W.N.W., G.C., J.W., P.S.) and Centre for Population Health Sciences (D.T., G.M.), University of Edinburgh, United Kingdom; Neurological & Mental Health Division, George Institute for Global Health, University of Sydney, Australia (R.I.L.); and Neuroimaging Sciences, Edinburgh, United Kingdom (J.W.).
Abstract
BACKGROUND AND PURPOSE: Prompt thrombolytic therapy with intravenous alteplase reduces disability after acute ischemic stroke. In an exploratory analysis, we examined whether long-term survival varied by baseline characteristics after alteplase. METHODS: In this open-treatment, international, randomized, controlled trial, ischemic stroke patients were randomly allocated <6 hours of onset to intravenous alteplase (0.9 mg/kg) plus standard care (n=1515) or standard care alone (n=1520). We followed patients to death, censoring when last known to be alive. We grouped patients by delay to randomization, and good or poor predicted prognosis (calculated from baseline National Institutes of Health Stroke Scale [NIHSS] score and age). We present absolute mortality differences between treated and control groups at 7 days, 6 months, and 18 months poststroke. RESULTS: Alteplase was not associated with a significant increase in mortality within 18 months (0.6% [95% confidence interval (CI), -2.9% to +4.2] P=0.72] in all patients with complete vital status (99.9%, 3034/3035). In patients randomized <3 hours of stroke, 18-month mortality was lower in the alteplase-treated group than the control group (40.6% [95% CI, 42.6-52.7] versus 47.8% [95% CI, 35.5-45.3]; P=0.0434]. The difference in 18-month mortality between alteplase-treated and control patients was greater in patients who were randomized early (<3 hours) compared with late (3-6 hours; +9% [95% CI, 1-17]; P=0.0317). Alteplase led to a greater improvement in 18-month survival in patients with a poor prognosis than in patients with a good prognosis (+8% [95% CI, 2-14]; P=0.0091). CONCLUSIONS: These exploratory analyses of the third International Stroke Trial (IST-3) trial support improving acute stroke patients' access to earlier alteplase treatment, treatment of patients with poor prognosis, and further randomized controlled trials in minor stroke to replicate these findings. CLINICAL TRIAL REGISTRATION URL: http://www.controlled-trials.com. Unique identifier: ISRCTN25765518.
BACKGROUND AND PURPOSE: Prompt thrombolytic therapy with intravenous alteplase reduces disability after acute ischemic stroke. In an exploratory analysis, we examined whether long-term survival varied by baseline characteristics after alteplase. METHODS: In this open-treatment, international, randomized, controlled trial, ischemic stroke patients were randomly allocated <6 hours of onset to intravenous alteplase (0.9 mg/kg) plus standard care (n=1515) or standard care alone (n=1520). We followed patients to death, censoring when last known to be alive. We grouped patients by delay to randomization, and good or poor predicted prognosis (calculated from baseline National Institutes of Health Stroke Scale [NIHSS] score and age). We present absolute mortality differences between treated and control groups at 7 days, 6 months, and 18 months poststroke. RESULTS: Alteplase was not associated with a significant increase in mortality within 18 months (0.6% [95% confidence interval (CI), -2.9% to +4.2] P=0.72] in all patients with complete vital status (99.9%, 3034/3035). In patients randomized <3 hours of stroke, 18-month mortality was lower in the alteplase-treated group than the control group (40.6% [95% CI, 42.6-52.7] versus 47.8% [95% CI, 35.5-45.3]; P=0.0434]. The difference in 18-month mortality between alteplase-treated and control patients was greater in patients who were randomized early (<3 hours) compared with late (3-6 hours; +9% [95% CI, 1-17]; P=0.0317). Alteplase led to a greater improvement in 18-month survival in patients with a poor prognosis than in patients with a good prognosis (+8% [95% CI, 2-14]; P=0.0091). CONCLUSIONS: These exploratory analyses of the third International Stroke Trial (IST-3) trial support improving acute stroke patients' access to earlier alteplase treatment, treatment of patients with poor prognosis, and further randomized controlled trials in minor stroke to replicate these findings. CLINICAL TRIAL REGISTRATION URL: http://www.controlled-trials.com. Unique identifier: ISRCTN25765518.
Authors: T G Kwiatkowski; R B Libman; M Frankel; B C Tilley; L B Morgenstern; M Lu; J P Broderick; C A Lewandowski; J R Marler; S R Levine; T Brott Journal: N Engl J Med Date: 1999-06-10 Impact factor: 91.245
Authors: William N Whiteley; Karsten Bruins Slot; Peter Fernandes; Peter Sandercock; Joanna Wardlaw Journal: Stroke Date: 2012-09-20 Impact factor: 7.914
Authors: Inke R König; Andreas Ziegler; Erich Bluhmki; Werner Hacke; Philip M W Bath; Ralph L Sacco; Hans C Diener; Christian Weimar Journal: Stroke Date: 2008-04-10 Impact factor: 7.914
Authors: Peter Sandercock; Richard Lindley; Joanna Wardlaw; Martin Dennis; Karen Innes; Geoff Cohen; Will Whiteley; David Perry; Vera Soosay; David Buchanan; Graham Venables; Anna Czlonkowska; Adam Kobayashi; Eivind Berge; Karsten Bruins Slot; Veronica Murray; Andre Peeters; Graeme J Hankey; Karl Matz; Michael Brainin; Stefano Ricci; Teresa A Cantisani; Gordon Gubitz; Stephen J Phillips; Arauz Antonio; Manuel Correia; Phillippe Lyrer; Ingrid Kane; Erik Lundstrom Journal: Trials Date: 2011-11-30 Impact factor: 2.279
Authors: Peter Sandercock; Joanna M Wardlaw; Richard I Lindley; Martin Dennis; Geoff Cohen; Gordon Murray; Karen Innes; Graham Venables; Anna Czlonkowska; Adam Kobayashi; Stefano Ricci; Veronica Murray; Eivind Berge; Karsten Bruins Slot; Graeme J Hankey; Manuel Correia; Andre Peeters; Karl Matz; Phillippe Lyrer; Gord Gubitz; Stephen J Phillips; Antonio Arauz Journal: Lancet Date: 2012-05-23 Impact factor: 79.321
Authors: Joanna M Wardlaw; Veronica Murray; Eivind Berge; Gregory del Zoppo; Peter Sandercock; Richard L Lindley; Geoff Cohen Journal: Lancet Date: 2012-05-23 Impact factor: 79.321
Authors: Martin Krueger; Wolfgang Härtig; Clara Frydrychowicz; Wolf C Mueller; Andreas Reichenbach; Ingo Bechmann; Dominik Michalski Journal: J Cereb Blood Flow Metab Date: 2016-01-01 Impact factor: 6.200